
zzso zzso necrosis factor zzso is a vascular targeting agent exploiting a zzso zzso zzso that selectively binds to zzso zzso zzso on zzso blood zzso zzso zzso zzso was shown between low doses of zzso and zzso 

The primary aim of this phase I trial was to verify the safety of zzso zzso combined with zzso in treating zzso solid zzso Secondary objectives included zzso zzso zzso and clinical zzso In all 15 patients received zzso zzso zzso zzso and zzso zzso zzso zzso both given zzso every 3 zzso 

No zzso toxicity occurred and the combination was well zzso Around two cases of zzso zzso lasting 2 days, and two cases of cardiac zzso zzso one zzso and the other zzso were zzso Only zzso of the adverse events were related to zzso and were zzso and zzso in zzso There was no apparent zzso interaction and the shedding of soluble zzso did not increase to zzso zzso zzso One partial response zzso at dose level zzso zzso zzso and 10 stable diseases zzso lasting for a median duration of zzso months, were zzso 

zzso plus zzso was administered safely and showed promising activity in patients zzso with zzso The dose level of zzso zzso zzso zzso plus zzso 75 zzso zzso was selected for phase II zzso 

